Presence of the insulin resistance in metabolic syndrome;Presencia de insulinorresistencia en síndrome metabólico

Revista Argentina de Endocrinologia y Metabolismo

Volumn 43, Issue 4, 2006, Pages 215-223

  Bonneau, Graciela Alicia ^a,b,d   Castillo Rascon, María Susana ^a,b   Pedrozo, W R ^a,b   Ceballos, Blanca ^b   Leiva, Ruth ^a   Blanco, Natalia ^a   Berg, Gabriela ^c  

^a UNIVERSIDAD NACIONAL DE MISIONES   (Argentina)

^b Hospital Dr Ramon Madariaga   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d NONE   (Argentina)

Author keywords

Cardiovascular risk factors; Insulin resistance; Metabolic syndrome

Indexed keywords

INSULIN; LIPID; LIPOPROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULINEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

EID: 33845437627     PISSN: 03264610     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Fleitas Esteves A. Síndrome X. Alto riesgo de enfermedad arterial. Rev. Cubana Angiol. y Cir. Vasc. 3(1):68-74; 2002.
2. Bloomgarden ZT. Definitions of the Insulin Resistance Syndrome. Diabetes Care. 27 (No3):824-830; 2004.
3. Gonzalez, C.D., Santoro, S.G., Sinay, I. Farmacología de la Insulinorresistencia: Situación actual y perspectivas. Rev Argent de Endocrinol Metab 41(3):159-169; 2004
4. Valmore Bermude P.; Climaco Cano P.; Mayerlim Medina R.; y col. Homeostasis Model Assessment (HOMA) en Pacientes Diabéticos tipo 2. Med. Int. (Caracas) Vol. 16 (3); 2000.
5. De Fronzo R. A., Tobin J.D., Andres R. The glucosa clamp technique: a method for cuantification of beta cell sensitivity to glucosa and of tissue sensitivity to insulin. Am. J. Phisiol. E214-E223; 1979.
6. Skrha J, Haas T, Sindelka G, y col. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 89:135-41; 2004
7. Haffner SM., Miettinen H., Stern M. The Homeostasis Model in the San Antonio Heart Study. Diabetes Care 20: 1087-1092. 1997.
8. Bonora E., Targher G., Alberiche M., y col. Homeostasis Model Assesment Closely Mirrors the Glucosa Clamp Technique in the Assesment of Insulin Sensitivity. Diabetes care 23: 57-63; 2000
9. Bloomgarden ZT. The 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care 27 (No2):602-609; 2004
10. Kuczmarski RJ, Carroll MD, Flegal KM, Troyano RP. Varying body mass index cut-off points to describe overweight prevalence among U.S. Adults: NHANES III (1988 to 1994). Obes Res. 5:542-548; 1997.
11. Hulthe, J; Bokemark, L.; Wikstrand, J y col. The Metabolic Syndrome, LDL particle size and atherosclerosis: The Atherosclerosis and Insulin Resitance (AIR) Study. Arterioscler Thromb. Vasc. Biol. 20(9): 2140-7; 2000.
12. Reilly MP; Rader D J. The Metabolic syndrome. More Than the Sum of this Parts?. Circulation. 108:1546-1551. 2003.-
13. Isomaa B y col. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 4: 683-689; 2001.
14. National Cholesterol Education Panel (NCEP). Adult Treatment Panel III (ATP III). JAMA 285:2486-97; 2001.
15. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva, World Health Organitation. WHO Technical Report Series, No 854:429-430; 1993.
16. Ascaso JF, Pardo S, Real JT, y col. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26:3320-5; 2003.
17. Mc Auley K., Williams S., Mann J., y col. Diagnosing Insulin Resistance in the General Population. Diabetes Care 24:460-464; 2001.
18. Graffigna M., Litwak L., Abdala M., y col. Determinación del Indice HOMA en sujetos presuntamente sanos. Estudio epidemiológico multicéntrico. (resultados preliminares). Rev. Arg. de Endocrinologia y Metabolismo 42(1):12-19; 2005.
19. Wolfthal D. y Buccini G. Insulinorresistencia y Sindrome metabólico. Bioquímica y Patología Clínica 68(1): 42-43; 2004.
20. Fontbonne A., Eschwege E., Cambien F., y col. Hypertriglyceridaemia as a risk factor of coronary Herat disease mortality in subjects with impaired glucosa tolerante or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetología 32(5):300-304; 1989.
21. Gastelú R. y Trebin C. Valores de Referencia de Insulina e Indice HOMA para una Metodología ECLIA: Bioquímica y Patología Clínica 68(1): 44; 2004.
22. Mc Laughlin T., Abbasi F., Reaven G. y col. Utilizacion de marcadores Metabolicos para la identificacion de Insulinorresistencia en sujetos obesos. Ann. Intern. Med. 139(10):802-804; 2003.
23. Ruibal G. Consenso sobre Diagnostico de Insulinorresistencia. Rev de Endocrinologia Gin. y Reproductiva 1:24-27; 2003.
24. Wallace T.A., Levy J.C., Matthews D.r. Use y Abuse of HOMA Modeling. Diabetes Care 27:1487-1495; 2004.
25. Coniglio R., Pino M., Cailotto M. y col. Indice de Insulinorresistencia y Sindrome metabolico en un grupo Poblacional del Sur Argentino. Rev. Arg. de Cardiología 3: 35-37; 2001.
26. Litwak L , Graffigna M., Abdala M., y col. Prevalencia de Factores de Riesgo Cardiovascular en sujetos presuntamente sanos. Estudio epidemiológico Multicéntrico (Capital federal y Gran Buenos Aires). Rev. Arg. de Endocrinologia y Metab. 41:206-213; 2004.
27. Bonora E., Kiechi S., Williet J. y col. Prevalence of Insulin Resistance in Metabolic Disorders. The Bruneck Study. Diabetes 47:1643-1648; 1998.
28. Lobo P.E., Martí M.L., Preiti M., y col. Ausencia de concordancia entre Insulinorresistencia y el Sindrome metabolico ATP III. Rev. Soc. Arg. de Diabetes 38(3):163; 2004.
29. Cheal K., Abassi F., Lamendola C., y col. Relationship to Insulin Resistance of Adult Treatment Panel III Diagnostic Criteria for Identification of the Metabolic Syndrome. Diabetes 53:1195-1200; 2004.
30. Liao Y., Kwon S., Wallace P. y col. Critical evaluation of Adult Treatment Panel III Criteria in Identifying Insulin Resistance with Dyslipemia. Diabetes Care 27(4):978-983; 2004.
31. Mc Laughlin T., Reaven G., Abbasi F., y col. Is there a Simple Way to Identify Insulin-Resistant Individuals al Increased Risk of Cardiovascular Disease? The American Journal of Cardiology 96:399-404; 2005.
32. Ascaso JE, Romero P, Real JT., y col. Abdominal obesity, Insulin resistance and metabolic syndrome in a southern European population. European Journal of Internal Medicine 14: 101-106; 2003.
33. Hanley A., Karter A., Festa A., y col. Factor Analysis of metabolic Syndrome Using Directly Measured Insulin Sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes 51: 2642-2647; 2002
34. Solymoss C., Bourassa M., Campeau L., y col. Effect of Increasing Metabolic Syndrome Score on Atherosclerotic Risk Profile and Coronary Artery Disease Angiografic Severity. The American Journal of Cardiology 93:159-165. 2004.
35. Wahrenberg H., Hertel K., Leijonhufvud B., y col. use of waist circumference to predict Insulin Resistance: retrospective study. BMJ Journal 330: 1363-1364; 2005.
36. Reaven G. Compensatory Hyperinsulinemia and the Development of an Atherogenic Lipoprotein Profile: the Price paid to Maintain Glucose Homeostasis in Insulin-Resistant Individuals. Endocrinology and Metabolism Clinics of North America 34: 49-62; 2005.
37. Flegal KM, Carroll MD, Ogden CI, Jonson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-7. 2002.